← The Wire
TNGXNasdaq
Tango Therapeutics, Inc.
Pharmaceutical Preparations · DE · CIK 1819133
Tango Therapeutics discovers and develops precision oncology therapies, including novel PRMT5 inhibitors for various cancers
red 8-K · 90d⚡ Elevated coverage
$5.04B
Market cap
$32.56
Last close
+3.5%
1D
+14.3%
5D
5.9M
Volume
Price · last 39 sessions+43.4%
May 4L $19.65 · H $32.90Jun 29
99
Total filings
Jun 23, 2026
Last filing
12/31
Fiscal year end
8-KExecutive ChangeJun 23, 20268-KMaterial AgreementJun 10, 2026424B5424B5Jun 10, 2026424B5424B5Jun 8, 20268-KReg FD Disclosure · Company UpdateJun 8, 20268-KShareholder VoteJun 4, 20268-KExecutive Change · Results of OperationsMay 13, 202610-Q10-QMay 13, 20268-KExecutive ChangeMay 8, 2026DEFA14ADEFA14AApr 17, 2026DEF 14ADEF 14AApr 17, 20268-KExecutive Change · Reg FD DisclosureApr 15, 20268-KResults of OperationsMar 5, 202610-K10-KMar 5, 2026SC 13D/ASC 13D/AFeb 10, 20268-KExecutive Change · Results of OperationsJan 8, 20268-KExecutive ChangeJan 5, 20268-KMaterial Agreement · Agreement TerminatedNov 21, 20258-KResults of OperationsNov 4, 202510-Q10-QNov 4, 20258-KMaterial Agreement · Equity IssuanceOct 24, 2025424B5424B5Oct 24, 20258-KResults of Operations · Company UpdateOct 23, 20258-KExecutive ChangeAug 25, 202510-Q10-QAug 5, 20258-KResults of OperationsAug 5, 20258-KBylaw Amendment · Shareholder VoteJun 6, 202510-Q10-QMay 12, 20258-KResults of OperationsMay 12, 2025DEFA14ADEFA14AApr 22, 2025DEF 14ADEF 14AApr 21, 202510-K10-KFeb 27, 20258-KResults of OperationsFeb 27, 20258-KResults of Operations · Reg FD DisclosureJan 13, 2025SC 13GSC 13GNov 20, 202410-Q10-QNov 6, 20248-KResults of Operations · Company UpdateNov 6, 202410-Q10-QAug 7, 20248-KResults of OperationsAug 7, 20248-KBylaw Amendment · Shareholder VoteJun 6, 20248-KReg FD Disclosure · Company UpdateMay 23, 202410-Q10-QMay 8, 20248-KResults of OperationsMay 8, 2024DEF 14ADEF 14AApr 29, 202410-K10-KMar 18, 20248-KResults of OperationsMar 18, 20248-KResults of OperationsFeb 7, 202410-Q10-QNov 8, 20238-KResults of OperationsNov 8, 2023SC 13GSC 13GSep 21, 20238-KExecutive ChangeAug 30, 2023SC 13GSC 13GAug 21, 20238-KMaterial Agreement · Equity IssuanceAug 10, 202310-Q10-QAug 7, 20238-KExecutive Change · Results of OperationsAug 7, 20238-KShareholder VoteJun 7, 202310-Q10-QMay 9, 20238-KResults of OperationsMay 9, 2023DEFA14ADEFA14AApr 24, 2023DEF 14ADEF 14AApr 24, 202310-K10-KMar 27, 20238-KResults of OperationsMar 27, 20238-KExecutive Change · Reg FD DisclosureFeb 28, 202310-Q10-QNov 10, 20228-KResults of OperationsNov 10, 202210-Q10-QAug 10, 20228-KResults of OperationsAug 10, 2022SC 13GSC 13GJul 11, 20228-KShareholder VoteJun 10, 202210-Q10-QMay 11, 20228-KResults of OperationsMay 11, 2022DEFA14ADEFA14AApr 26, 2022DEF 14ADEF 14AApr 26, 202210-K10-KMar 28, 20228-KResults of OperationsMar 28, 2022SC 13GSC 13GFeb 14, 2022SC 13GSC 13GFeb 9, 202210-Q10-QNov 9, 20218-KResults of OperationsNov 9, 2021S-1S-1Sep 10, 2021
Insider Activity
In the 90 days to Mar 25, 2026: 3 sold $2.0M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 25, 2026 | Crystal AdamPresident, R&D | Sell | 12,000 | $20.11 | $241K |
| Mar 5, 2026 | Crystal AdamPresident, R&D | Sell | 20,251 | $15.00 | $304K |
| Feb 25, 2026 | Crystal AdamPresident, R&D | Sell | 54,345 | $12.77 | $694K |
| Feb 3, 2026 | Weber BarbaraDirector, Executive Chair | Sell | 30,186 | $12.26 | $370K |
| Feb 3, 2026 | Crystal AdamPresident, R&D | Sell | 18,251 | $12.26 | $224K |
| Feb 3, 2026 | Beckman DaniellaChief Financial Officer | Sell | 10,204 | $12.26 | $125K |
| Feb 3, 2026 | Weber BarbaraDirector, Executive Chair | Sell | 333 | $12.90 | $4K |
| Feb 3, 2026 | Crystal AdamPresident, R&D | Sell | 201 | $12.90 | $3K |
| Feb 3, 2026 | Beckman DaniellaChief Financial Officer | Sell | 113 | $12.90 | $1K |
| Oct 23, 2025 | Trv Gp Iv, LlcTenPercentOwner | Sell | 477,401 | $10.15 | $4.8M |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
⚡ Elevated coverageCoverage (30d): 3 reputable articles · skews ▲ positive.
Barron'sTango Therapeutics Stock Soars 53% After ’Unprecedented’ Data on Pancreatic Cancer Treatment21d agoInvestor's Business DailyBiotech Surges 45% On Eye-Popping Pancreatic Cancer Test21d agoBloomberg.comTango Soars as Study Shows Its Drug Can Help Shrink Tumors21d ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance